About RNA binding protein fox-1 homolog 3
RNA binding protein fox-1 homolog 3 (RBFOX3) is a protein
from Homo sapiens identified by UniProt accession
A6NFN3, 312 residues long.
MolForge cross-references it against 0 known binders and
296 disease associations.
Target properties
| Protein name | RNA binding protein fox-1 homolog 3 |
| UniProt accession | A6NFN3 |
| Gene | RBFOX3 |
| Organism | Homo sapiens |
| Length | 312 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (296)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- Rolandic epilepsy · score 0.34
- childhood epilepsy with centrotemporal spikes · score 0.33
- autosomal dominant compelling helio-ophthalmic outburst syndrome · score 0.31
- metastasis measurement · score 0.26
- disease progression measurement · score 0.26
- 3-hydroxypropylmercapturic acid measurement · score 0.25
- 3-hydroxy-1-methylpropylmercapturic acid measurement · score 0.25
- Orofacial cleft · score 0.20
- generalised epilepsy · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NFN3-F1 | alphafold | PREDICTED | 61.56 | — |
Amino-acid sequence (312 residues)
MAQPYPPAQY PPPPQNGIPA EYAPPPPHPT QDYSGQTPVP TEHGMTLYTP AQTHPEQPGS EASTQPIAGT QTVPQTDEAA QTDSQPLHPS DPTEKQQPKR LHVSNIPFRF RDPDLRQMFG QFGKILDVEI IFNERGSKGF GFVTFETSSD ADRAREKLNG TIVEGRKIEV NNATARVMTN KKTGNPYTNG WKLNPVVGAV YGPEFYAVTG FPYPTTGTAV AYRGAHLRGR GRAVYNTFRA APPPPPIPTY GAVVYQDGFY GAEIYGGYAA YRYAQPAAAA AAYSDSYGRV YAAADPYHHT IGPAATYSIG TM
Explore RNA binding protein fox-1 homolog 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets